Optimization of warfarin dose by population-specific pharmacogenomic algorithm

Pharmacogenomics Journal

Volumn 12, Issue 4, 2012, Pages 306-311

  Pavani, A ^a   Naushad, S M ^a   Rupasree, Y ^a   Kumar, T R ^a   Malempati, A R ^a   Pinjala, R K ^a   Mishra, R C ^a   Kutala, V K ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

CYP2C9; pharmacogenomic algorithm; VKORC1; warfarin

Indexed keywords

CYTOCHROME P450 2C9; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIETARY INTAKE; GENETIC ALGORITHM; GENETIC LINKAGE; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HETEROZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; VITAMIN INTAKE;

ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; VITAMIN K; WARFARIN;

EID: 84864364455     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.4     Document Type: Article

References (20)

1. El Rouby S, Mestres CA, LaDuca FM, Zucker ML. Racial and ethnic differences in warfarin response. J Heart Valve Dis 2004; 13: 15-21.
2. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol 2006; 13: 357-361. (Pubitemid 44168457)
3. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74. (Pubitemid 26425815)
4. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698. (Pubitemid 34289221)
5. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of vkorc1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293. (Pubitemid 40740552)
6. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6: 1663-1670.
7. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
8. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
9. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
10. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY et al. Interethnic variability of warfarin maintenance requirement is explained by vkorc1 genotype in an asian population. Clin Pharmacol Ther 2006; 79: 197-205.
11. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 2005; 19: 101-105. (Pubitemid 40204352)
12. International Warfarin Pharmacogenetics ConsortiumKlein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
13. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84: 1079-1094.
14. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37: 3-24.
15. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-2480. (Pubitemid 46425891)
16. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT et al. Warfarin pharmacogenetics: a single vkorc1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
17. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-186. (Pubitemid 46754413)
18. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009; 10: 1243-1255.
19. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010; 70: 234-240.
20. D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 2004; 89: 1510-1516.